![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
X
20
Fresenius Kabi Oncology Limited Kalyani In, based in India, is a pharmaceutical company that stands out with its certifications from WHO-GMP.
One of their significant offerings is Bicalutamide, supported by a 'Valid' Certificate of Suitability (CEP) with the number R1-CEP 2012-369 - Rev 00
This Chemical Type CEP, issued on May 20, 2021, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.
Substance Number 2196 associated with this CEP further emphasizes